Ionis Pharmaceuticals
IONS
213 hedge funds and large institutions have $4.13B invested in Ionis Pharmaceuticals in 2013 Q4 according to their latest regulatory filings, with 34 funds opening new positions, 83 increasing their positions, 73 reducing their positions, and 24 closing their positions.
42% more first-time investments, than exits
New positions opened: 34 | Existing positions closed: 24
14% more repeat investments, than reductions
Existing positions increased: 83 | Existing positions reduced: 73
6% more capital invested
Capital invested by funds: $3.91B → $4.13B (+$219M)
4% more funds holding
Funds holding: 204 → 213 (+9)
0% more funds holding in top 10
Funds holding in top 10: 5 → 5 (0)
33% less call options, than puts
Call options by funds: $45.9M | Put options by funds: $68.7M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
+$27.8M |
| 2 |
ACM
Apex Capital Management
Dayton,
Ohio
|
+$27M |
| 3 |
WRF
Waddell & Reed Financial
Overland Park,
Kansas
|
+$18M |
| 4 |
RIM
Rainier Investment Management
Seattle,
Washington
|
+$18M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
+$17.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GIM
Granahan Investment Management
Waltham,
Massachusetts
|
-$31.6M |
| 2 |
BB
BB Biotech
Schaffhausen,
Switzerland
|
-$28M |
| 3 |
PC
PointState Capital
New York
|
-$27.2M |
| 4 |
MG
Meditor Group
Hamilton,
Bermuda
|
-$18.4M |
| 5 |
BA
BlackRock Advisors
Wilmington,
Delaware
|
-$17.5M |
IONS Hedge Fund Activity: Q4 2013 in Review
213 of the 3,445 institutional investors tracked by Wall St. Rank reported a position in Ionis Pharmaceuticals (IONS) for Q4 2013, worth a combined $4.13B — up 5.6% from $3.91B a quarter earlier.
Buyers outnumbered sellers: 34 funds opened new IONS positions and 24 closed out — a net gain of 10 holders — while 83 added to existing stakes and 73 trimmed.
The largest buyer was Sectoral Asset Management, adding an estimated $27.8M. The largest seller was Granahan Investment Management, exiting entirely with an estimated $31.6M sold.
- 213 institutional investors held Ionis Pharmaceuticals (IONS) as of Q4 2013, up from 204 in Q3 2013.
- Funds reported $4.13B of Ionis Pharmaceuticals stock for Q4 2013, up 5.6% quarter-over-quarter.
- 34 funds opened new Ionis Pharmaceuticals positions in Q4 2013 and 24 closed out, a net change of +10 holders.
- The largest Ionis Pharmaceuticals buyer in Q4 2013 was Sectoral Asset Management, an estimated $27.8M added.
- The largest Ionis Pharmaceuticals seller in Q4 2013 was Granahan Investment Management, an estimated $31.6M sold.
Based on aggregated 13F filings for Q4 2013.